Retatrutide in Abu Dhabi: Research Status, Formats & COA Proof
The Abu Dhabi-specific view for researchers: approval status, the six documented formats, archived batch COA proof, and the handling variables that matter in the capital.
As of July 7, 2026, "retatrutide Abu Dhabi" is a research-documentation question, not a pharmacy-access question. The capital has no approved retatrutide medicine route. What Abu Dhabi researchers need is the same proof stack used across the Emirates: a published, re-verifiable Janoshik COA tied to a named batch, a documented 2–8°C handling standard, and an unbroken custody record across the Dubai-to-Abu Dhabi leg. For the consolidated UAE reference, use the Retatrutide UAE hub.
Want the full UAE reference record first? See the Retatrutide UAE page, the Dubai research guide, the pen format guide, and the COA library.
Is Retatrutide Available in Abu Dhabi for Research Use?
Quick answer: Retatrutide is not MoHAP-approved and has no pharmacy or clinic route in Abu Dhabi. It appears in the capital only as in-vitro laboratory research material.
Retatrutide (LY-3437943) is an investigational triple-agonist peptide, not a licensed medicine in the UAE, so it does not appear on Abu Dhabi pharmacy shelves. Research institutions, university labs, and private research facilities in Abu Dhabi reference the compound for in-vitro laboratory work only; its approval status is tracked separately. Remy Peptides is a Dubai-based (Al Barsha 1) research publisher and documents retatrutide strictly as laboratory reference material. Batch purity is independently verifiable through the published Janoshik Analytical COAs.
- Retatrutide is investigational and not stocked in Abu Dhabi pharmacies as of July 7, 2026 — access is research-use only.
- The documented research record spans the 30mg, 20mg, 10mg and 40mg prefilled pens plus the 10mg and 40mg vials — led by the 30mg pen (300 clicks at 0.1mg/click), batch RETP002 at 99.262% HPLC.
- The Dubai-to-Abu Dhabi leg is short, but the 2–8°C custody record across it is what keeps a purity figure meaningful in a protocol.
- Four batches carry published certificates; the 10mg pen has none, and this page says so rather than filling the gap.
- Every archived batch is backed by an independent Janoshik HPLC certificate of analysis with a re-verifiable key.
Retatrutide Research-Use Status in the UAE and Abu Dhabi
Quick answer: Retatrutide (LY-3437943) is Eli Lilly's investigational once-weekly triple agonist targeting GLP-1, GIP, and glucagon receptors. It remains in Phase 3 development (TRIUMPH programme) and is not approved by the FDA, EMA, or UAE MoHAP. Research-grade formats are documented here for in-vitro laboratory context only.
Retatrutide simultaneously activates three metabolic receptors — GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). In a pivotal Phase 2 trial published in the New England Journal of Medicine (DOI: 10.1056/NEJMoa2301972), the highest dose reported a mean 24.2% body-weight reduction over 48 weeks. Eli Lilly's Phase 3 TRIUMPH programme has continued to read out through 2026, but Lilly has not announced an NDA filing date, and retatrutide remains investigational without FDA, EMA, or UAE approval.
For Abu Dhabi, the practical consequence is unchanged: there is no approved retatrutide medicine and no clinical dispensing route in the capital. Any UAE clinical availability would require separate regulatory review by the UAE Ministry of Health and Prevention (MoHAP) after Phase 3 completion. Until then, retatrutide in Abu Dhabi is a research-use compound only. The full regulatory timeline is tracked on our retatrutide approval status page, and UAE study listings are covered in the retatrutide clinical trials UAE review.
How Abu Dhabi Labs Evaluate a Retatrutide Source
Quick answer: Retatrutide is a pre-approval investigational compound with no pharmacy or clinic route, so the only auditable signal is documentary — a batch-specific Janoshik COA whose verify key can be re-checked at the issuing laboratory, plus a stated handling standard.
Prefilled pens are the preferred format for Abu Dhabi labs for the same reasons they are in Dubai: they remove the reconstitution step that introduces the primary contamination vector, provide click-based precision (0.1mg per click on the 30mg pen), and travel in temperature-controlled packaging that protects material integrity across the UAE summer. Before relying on any source, Abu Dhabi researchers should look for a batch-specific Janoshik COA with a re-verifiable HPLC purity value, published format specifications, a stated 2–8°C handling standard, and a named jurisdiction with verifiable contact channels. Our COA verification walkthrough and step-by-step source-verification checklist apply identically in the capital.
The Documented Retatrutide Format Record
Quick answer: Six retatrutide research formats appear in the UAE record — 30mg, 20mg, 10mg and 40mg prefilled pens plus 10mg and 40mg lyophilized vials. Four of the six carry a published Janoshik certificate; the 10mg pen does not.
Format matters to an Abu Dhabi laboratory record for two reasons. First, prefilled pens remove the reconstitution step, which removes the dominant contamination vector and the main source of volumetric error. Second, lyophilized vials require a documented reconstitution, so the diluent, the volume and the resulting concentration all have to be recorded before any downstream figure means anything.
- 30mg pen — 300 clicks at 0.1mg/click; batch RETP002, 99.262% HPLC.
- 20mg pen — batch RET-20-C-2604-001, 99.841% HPLC.
- 10mg pen — no published certificate.
- 10mg vial — batch RET-20-V-2604-001, 99.741% HPLC.
- 40mg vial — batch RT-40-V-001, 99.692% HPLC, sterility-tested.
The pen format guide covers the click scale in detail, and the reconstitution calculator handles the vial arithmetic. Both are laboratory record-keeping references, not dosing guidance. The consolidated UAE record sits on Retatrutide UAE.
Cold-Chain Custody on the Dubai–Abu Dhabi Leg
Quick answer: Peptide reference material is documented against a 2–8°C standard. The Dubai–Abu Dhabi road leg is short, but UAE ambient temperatures routinely exceed 45°C in summer, so an undocumented custody gap is enough to detach a laboratory record from the certificate it cites.
Insulated, temperature-controlled packaging is the baseline for moving peptide reference material across the Emirates. What matters for the record is not the packaging claim but the log: departure time, transit duration, peak internal temperature, and receipt condition. A short excursion that is measured and recorded is a data point; an unmeasured one invalidates the chain, because there is no way afterwards to distinguish it from a long one.
This is the single largest integrity variable in the region — larger than format choice and larger than storage duration at the receiving laboratory, because it is the leg over which the receiving lab has the least visibility. For the underlying stability literature, see the peptide stability and storage guide.
COA and Purity Proof for Abu Dhabi Labs
Each archived retatrutide batch was HPLC-verified by Janoshik Analytical, an independent third-party laboratory based in the Czech Republic, and its batch-specific Certificate of Analysis is published in full. The 30mg pen batch RETP002 reports 99.262% HPLC; sibling batches include the 20mg pen RET-20-C-2604-001 at 99.841% and the 40mg vial RT-40-V-001 at 99.692% (sterility-tested). Abu Dhabi researchers can re-verify any published batch themselves on janoshik.com and cross-check publisher identity via contact verification.
Retatrutide vs Semaglutide and Tirzepatide in Trial Data
Abu Dhabi researchers comparing metabolic receptor agonists usually start from the receptor count, which correlates with observed efficacy in published trials. The table below summarises reported trial figures for context; these are clinical-trial observations, not product claims or guidance for use.
| Feature | Semaglutide (Wegovy) | Tirzepatide (Mounjaro/Zepbound) | Retatrutide |
|---|---|---|---|
| Receptors targeted | GLP-1 only (single agonist) | GLP-1 + GIP (dual agonist) | GLP-1 + GIP + glucagon (triple agonist) |
| Reported mean weight reduction in trials | ~15% at 68 weeks (STEP 1, phase 3) | ~21% at 72 weeks (SURMOUNT-1, 15 mg, phase 3) | ~24% at 48 weeks (phase 2, NEJM 2023) |
| Approval status | FDA/EMA approved for weight management | FDA/EMA approved for weight management | Investigational — not approved by FDA, EMA, or UAE MoHAP |
| Mechanism note | Appetite/satiety via GLP-1 pathway | Adds GIP-driven insulin and appetite effects | Adds glucagon agonism, linked in trials to higher energy expenditure and hepatic lipid oxidation |
For the full receptor, dosing, and trial breakdown, see our Retatrutide vs Tirzepatide vs CagriSema comparison. For a broader regional read, this page sits alongside the Dubai research guide and the Retatrutide in Saudi Arabia verification page.
Our Research Standards
This article combines peer-reviewed retatrutide trial literature with a July 7, 2026 review of the UAE research-use record and Abu Dhabi handling conditions. Batch proof is anchored to Janoshik COA RETP002 (99.262% HPLC). Retatrutide remains investigational; nothing here is a treatment, dosing, or human-use claim. Read our editorial policy →
References
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972.
- ClinicalTrials.gov. TRIUMPH retatrutide clinical trial program. NCT05929066.
- Janoshik Analytical. Certificate of Analysis, batch RETP002 — 99.262% HPLC. Reviewed July 7, 2026.
- Remy Peptides. Retatrutide UAE — documented research format record. Reviewed July 7, 2026.
Read the Retatrutide UAE hub, the pen format guide, the COA library, and contact verification together.